Sanofi-Aventis APAC Business Development VP Arjun Oberoi On Innovation Pacts And Deal-Making In Asia: An Interview With PharmAsia News (Part 2 of 2)
Arjun Oberoi, Sanofi-Aventis' vice president for business development Asia Pacific, mirrors his company's leadership ambitions in the Asian markets. Open to calculated risks and high on energy, Oberoi has played a leading role in clinching a few important deals for Sanofi such as last year's acquisition of China OTC play BMP Sunstone and its joint venture with Minsheng Pharmaceutical Group ('Sanofi Expands Consumer Health Reach With New Joint Venture In China,' PharmAsia News, Feb. 1, 2010).
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
The FDA has paused Gilead’s HIV trials of GS-1720 and GS-4182 over safety concerns. The company’s upcoming PrEP PDUFA looks to be unaffected.
Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.